US Earnings Financial Results SEC Filings — May 06, 2026
Across 50 Q1 2026 filings, mixed sentiments dominate (44/50 mixed or negative), with revenue growth averaging +15% YoY in outperformers like tech (AMD +38%, Arista +35%, Lumentum +90%) but declines in energy (Talos -8%), diagnostics (QuidelOrtho -10.5%), and utilities (Tucson Electric -7.5%); margins compressed in 28/50 companies (avg -150 bps where noted, e.g., Atkore -27% gross profit drop). Net income swung positive in turnaround stories (Taboola + from loss, JBT Marel +$45M from -$173M loss) but widened losses in biotechs (Ultragenyx -23% worse) and amid impairments (Talos $145M charge). Capital returns strong with buybacks (United Therapeutics $1.5B, Arista prior $787M but paused) and dividends (Yum +$0.04/share YoY), though cash piles shrank QoQ in 32/50 (avg -15%). Acquisitions boosted assets (Pinnacle doubled to $122B, Fresh Del Monte +11% QoQ) but integration costs pressured EPS. Portfolio trend: Tech/healthcare M&A active, financials resilient via deals; watch biotech catalysts like Polomar trials (Feb 2026). Implications: Favor tech growth names, avoid margin-squeezed industrials; sector rotation to strong cash flow generators amid capex surges.